Table 1 Patient characteristics at baseline

Male sex, n (%)

11 (100)

Age (years) ^a

35 (32–45)

Body weight (kg) ^a

56.1 (51.6–67.3)

BMI (kg/m²) ^a

18.2 (17.6–22.8)

BSA (m²)

1.69 (1.60–1.79)

Serum creatinine (mg/dL) ^a

0.80 (0.70–0.80)

eGFR (mL/min · 1.73 m²) ^a

96.1 (81.9–103.1)

CKD stage, n (%)

1

7 (63.6)

2

4 (36.4)

3

0 (0)

4

0 (0)

5

0 (0)

CD4⁺ cell count (/μL) ^a

119 (37–211)

HIV RNA viral load (log₁₀/mL) ^a

4.83 (4.61–5.85)

Protease inhibitors (ritonavir-boosted), n (%)

7 (63.6)

Protease inhibitors (unboosted), n (%)

0 (0)

NNRTIs, n (%)

0 (0)

INSTIs, n (%)

4 (36.4)

Concurrent use of a nephrotoxic drug, n (%)

4 (36.4)

Hypertension, n (%)

0 (0)

Diabetes, n (%)

0 (0)

Hepatitis B, n (%)

3 (27.3)

Hepatitis C, n (%)

0 (0)

Plasma TFV concentration (ng/mL) ^a

64.0 (56.0–90.5)